Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.
The number of Americans taking attention deficit hyperactivity disorder medicines rose 36 percent in 2012 from 2008, led by an surge among women, according to drug-benefits manager Express Scripts Holding Co.
Morgan Stanley and Goldman Sachs Group Inc. both decided last month that it was worth losing millions of dollars in fees to get credit on a big merger they didn’t work on, four people with knowledge of the matter said.
Teva Pharmaceutical Industries Ltd. is using records from its 24-hour support hotline in the U.S. to persuade thousands of multiple sclerosis patients to switch from its biggest-selling drug, Copaxone, to a new version that has patent protection until 2030.
John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.
GlaxoSmithKline Plc Chief Financial Officer Simon Dingemans said the pharmaceutical industry should expect to see “many more” shifts over which drugs U.S. insurers cover than in the past, driven by pharmacy-benefits managers.